Pieris and Sanofi Broaden Existing Collaboration
--Deal Expanded to Include Additional Multispecific Anticalins^®--
FREISING, Germany -- April 10, 2013
Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing
discovery and development partnership to include a novel multispecific
Anticalin^® program. Under the existing framework of the 2010 agreement, the
new program will entitle Pieris to an upfront payment from Sanofi and
committed research funding as well as payments for the achievement of
research, preclinical, regulatory and commercial milestones. Specific
financial terms were not disclosed.
“Following more than two years of successful collaboration in this
multi-program agreement, the expansion demonstrates that the Anticalin
technology can deliver key differentiation over conventional biologic
approaches, including the development of multispecific targeted therapeutics,”
said Stephen Yoder, CEO of Pieris. “Sanofi and Pieris will continue to advance
both existing and new programs, building on the excellent team chemistry
between our organizations.”
Anticalin-branded proteins represent a novel generation of targeted protein
therapeutics derived from human lipocalins, rationally engineered to solve for
the pharmacological and pharmaceutical limitations of both protein- and
non-protein-based drug platforms. The multispecific approach, whereby the DNA
of individual Anticalins can be pieced together to yield a fusion protein,
offers the potential for creating new biology and synergistic efficacy by
addressing multiple targets with a single drug. Additional benefits include
improved convenience, accelerated development timelines, ease of manufacturing
and reduced cost.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Pieris AG is an independent, clinical-staged biotechnology company advancing
its proprietary Anticalin^® technology to create differentiated drugs that are
safer and more effective than conventional approaches. Exclusive to Pieris,
Anticalin-branded proteins promise to address high-unmet medical needs and
expand the potential of targeted therapeutics. Pieris’ pipeline ranges from
its lead compound, which has completed a Phase I clinical trial, to multiple
Anticalins in preclinical development across a range of therapeutic areas. The
company currently has ongoing discovery and development collaborations with
Daiichi Sankyo, the Sanofi Group and Allergan.
Privately held, Pieris has been funded by premier biotechnology-focused
venture capital, including lead investors OrbiMed Advisors and Global Life
Science Ventures. For more information, please visit: www.pieris-ag.com.
Anticalin^®, Anticalins^® are registered trademarks of Pieris AG.
Stephen Yoder, CEO
+49 (0) 8161 1411 400
+49 172 861 8540
Press spacebar to pause and continue. Press esc to stop.